Abstract:Propose: Instant blood-mediated inflammatory reaction (IBMIR) causes significant peri-transplant islet damage following intraportal transplantation. IBMIR is initiated and perpetuated by a cascade of cellular and soluble innate immune responses, including high-mobility group box 1, tissue factor, macrophage chemoattractant protein-1, and interleukin-1β. Thrombomodulin (TM) regulates coagulation and suppresses inflammatory functions of neutrophils and macrophages while CD47 inhibits phagocytosis by macrophages, reducing inflammation and tissue damage. The main objective of this study was to exploit the immunomodulatory efficacy of these two molecules to mitigate IBMIR. Method: Pancreatic islets were biotinylated, followed by transient and positional display on their surface novel forms of TM (SA-TM) and CD47 (SA-CD47) chimeric with a modified form of streptavidin by taking the advantage of strong affinity between biotin and streptavidin. The viability and function of the engineered islets as well as their ability to mitigate IBMIR were assessed. Co-engineered islets were transplanted intraportally into streptozotocin diabetic syngeneic recipients (150 IEQ/mouse). Unmodified islets or islets engineered with SA-TM served as control. Blood glucose levels were monitored and graft function was assessed using an intraperitoneal glucose tolerance test. Flow cytometry and transcriptomic analysis were conducted on graft recipients at different times post-transplantation. Results: Islets were successfully engineered with SA-TM/SA-CD47 combination without affecting their viability and function. SA-TM/SA-CD47 on rat splenocytes inhibited phagocytosis by mouse macrophages in vitro. Similarly, bone marrow cells engineered with SA-TM/SA-CD47 were resistant to clearance in allogeneic hosts. In an ex vivo blood loop assay, SA-TM/SA-CD47 prevented islet damage associated with the down-regulation of various inflammatory mediators driving IBMIR. In a syngeneic minimal mass model of intraportal islet transplantation, SA-TM/SA-CD47-engineered islets had enhanced engraftment as compared with SA-TM-engineered islets or unmodified islets. The enhanced engraftment was associated with a significant decrease in intragraft proinflammatory cells and transcritps involved in IBMIR. Conclusion: Engineering islets to codisplay on their surface SA-TM and SA-CD47 molecules as regulators of innate immune responses effectively inhibits peri-transplant islet graft loss with implications for both autologous and allogeneic islet transplantation. Funded in parts by NIH R01AI121281 award.

Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression

Immune Modulation of Co-Transplantation Mesenchymal Stem Cells with Islet on T and Dendritic Cells.

Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Cotransplantation of Mesenchymal Stem Cells and Immature Dendritic Cells Potentiates the Blood Glucose Control of Islet Allografts

The Effect of Mouse Bone Marrow-Derived Mesenchymal Stem Cells on Islet Graft Rejection

Adipose Tissue-Derived Mesenchymal Stromal Cells Modulate Inflammatory Response and Improve Allograft Islet Transplant in Mice Model of Type 1 Diabetes

Potential roles of mesenchymal stromal cells in islet allo- and xenotransplantation for type 1 diabetes mellitus

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

Immunogenicity of allogeneic mesenchymal stem cells transplanted via different routes in diabetic rats

Co-transplantation of human adipose-derived mesenchymal stem cells with neonatal porcine islets within a prevascularized subcutaneous space augments the xenograft function

A novel prevascularized tissue-engineered chamber as a site for allogeneic and xenogeneic islet transplantation to establish a bioartificial pancreas

Low-Dose Interleukin-2 Combined With Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Regulatory T Cells and Prolonged Human Islet Allograft Survival in Humanized Mice

Local Immunomodulatory Strategies to Prevent Allo‐Rejection in Transplantation of Insulin‐Producing Cells

Human amniotic mesenchymal stem cell-islet organoids enhance the efficiency of islet engraftment in a mouse diabetes model

201.1: Co-engineering Pancreatic Islets with Novel Forms of Thrombomodulin and CD47 As an Effective Means of Mitigating Instant Blood-Mediated Inflammatory Reaction

Intrapancreatic MSC transplantation facilitates pancreatic islet regeneration

Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol

Co-Transplantation of lslets with Mesenchymal Stem Cells and lmmature Dendritic Cells in the Treatment of Mouse Diabetes

Multipotent Mesenchymal Stromal Cells Interact and Support Islet of Langerhans Viability and Function

[The Effect of Co-Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells and Islet on Maturation and Function of Bone Marrow-Derived Dendritic Cells in Recipient Mice].